danДоклады Национальной академии наук БеларусиDoklady of the National Academy of Sciences of Belarus1561-83232524-2431The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1561-8323-2024-68-3-220-228dan-1194Research ArticleБИОЛОГИЯBIOLOGYВлияние полиморфизма гена VEGF на выживаемость пациентов при немелкоклеточном раке легкогоEffect of VEGF gene polymorphism on the survival of a patient with non-small cell lung cancerШепетькоМ. Н.ShapetskaM. N.

Шепетько Михаил Николаевич – канд. мед. наук, доцент

пр. Дзержинского, 83, 220116, Минск

Shapetska Michail N. – Ph. D. (Medicine), Assistant Professor

83, Dzerzhinsky Ave., 220116, Minsk

shepetjko@gmail.comМихаленкоЕ. П.MikhalenkaA. P.

Михаленко Елена Петровна – канд. биол. наук, вед. науч. Сотрудник

ул. Академическая, 27, 220072, Минск

Mikhalenka Alena P. – Ph. D. (Biology), Leading Researcher

27, Akademicheskaya Str., 220072, Minsk

E.Michalenko@igc.byЩаюкА. Н.ShchayukA. N.

Щаюк Анна Николаевна – канд. биол. наук, ст. науч. Сотрудник

ул. Академическая, 27, 220072, Минск

Shchayuk Anna N. – Ph. D. (Biology), Senior Researcher

27, Akademicheskaya Str., 220072, Minsk

anna.shchayuk@tut.byМириленкоЛ. В.MirilenkoL. V.

Мириленко Людмила Владимировна – канд. мед. наук, доцент

223040, агр. Лесной, Минский р-н

Mirilenko Ludmila V. – Ph. D. (Medicine), Assistant Professor

223040, Lesnoy, Minsk region

ludamirilen@gmail.comГорбатенкоЛ. В.GorbatenkoL. V.

Горбатенко Лариса Владимировна – врач-реаниматолог

пр. Независимости, 64, 220013, Минск

Gorbatenko Ludmila V. – Resuscitator

64, Nezavisimosti Ave., 220013, Minsk

shepetjko@gmail.comКильчевскийА. В.KilchevskyA. V.

Кильчевский Александр Владимирович – академик, д-р биол. наук, профессор, гл. науч. Сотрудник

ул. Академическая, 27, 220072, Минск

Kilchevsky Aleksandr V. – Academician, D. Sc. (Biology), Professor, Chief Researcher

27, Akademicheskaya Str., 220072, Minsk

kilchev@presidium.bas-net.byБелорусский государственный медицинский университетBelarusian State Medical UniversityИнститут генетики и цитологии НАН БеларусиInstitute of Genetics and Cytology of the National Academy of Sciences of BelarusРНПЦ онкологии и медицинской радиологии им. Н. Н. АлександроваN. N. Alexandrov National Cancer CentreМинский городской клинический онкологический центрMinsk City Clinical Oncology Center202408072024683220228Copyright © Шепетько М.Н., Михаленко Е.П., Щаюк А.Н., Мириленко Л.В., Горбатенко Л.В., Кильчевский А.В., 20242024Шепетько М.Н., Михаленко Е.П., Щаюк А.Н., Мириленко Л.В., Горбатенко Л.В., Кильчевский А.В.Shapetska M.N., Mikhalenka A.P., Shchayuk A.N., Mirilenko L.V., Gorbatenko L.V., Kilchevsky A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://doklady.belnauka.by/jour/article/view/1194

Рак легкого занимает первые позиции в структуре смертности от онкологических заболеваний во многих экономически развитых регионах мира. Цель данной работы состояла в изучении влияния полиморфных вариантов rs2010963 (G-634C), rs699947 (A-2578C) и rs3025039 (C+936T) гена VEGF, кодирующего эндотелиальный фактор роста сосудов, на общую (ОВ) и скорректированную (СВ) выживаемость пациентов с немелкоклеточным раком легкого (НМРЛ) I–III стадий. Установлена ассоциация СВ с полиморфными вариантами rs2010963 (G-634C) и rs699947 (A-2578C). Одногодичная СВ у носителей генотипа -634G/C составила 81,9 ± 3,9 %, у носителей генотипа -634G/G – 92,8 ± 2,5 %, р = 0,016; двухлетняя СВ: у носителей генотипа -634G/C – 70,4 ± 4,6 % и у носителей генотипа -634G/G – 84,3 ± 3,5 %, р = 0,015 и трехлетняя СВ: у носителей генотипа -634G/C – 63,0 ± 4,9 %, у носителей генотипа -634G/G – 76,7±4,1 %, р = 0,029. Одногодичная и двухгодичная СВ у носителей генотипа -2578А/А была достоверно выше, чем у носителей генотипа -2578С/С (р = 0,015 и р = 0,042 соответственно). Таким образом, в исследовании показано влияние полиморфных вариантов гена VEGF на выживаемость пациентов с НМРЛ в первые три года после постановки диагноза.

Currently, much attention is paid to studying the vascular endothelial growth factor (VEGF) that stimulates angiogenesis, as a potential target for antiangiogenic therapy. The purpose of this work was to study the effect of polymorphic variants rs2010963 (G-634C), rs699947 (A-2578C), and rs3025039 (C+936T) of the VEGF gene, encoding a vascular endothelial growth factor, on the overall (OS) and adjusted survival (AS) of patients with non-small cell lung cancer (NSCLC) at stages I–III. The effect of VEGF rs699947 polymorphic variants on the extent of tumor spread was shown. A connection between AS and polymorphic variants rs2010963 (G-634C) and rs699947 (A-2578C) was established. The one-year adjusted survival (AS) in the -634G/C genotype carriers was 81.9 ± 3.9 %; in the -634G/G genotype carriers – 92.8 ± 2.5 %; and p = 0.016 was the significance level. Two-year AS was as follows: in the carriers of the -634G/C genotype was 70.4 ± 4.6 %; in the carriers of the -634G/G genotype – 84.3 ± 3.5 %; and p = 0.015. Three-year AS: in the carriers of the -634G/ genotype C was 63.0 ± 4.9 %; in the carriers of the -634G/G genotype – 76.7 ± 4.1 %; and p = 0.029. One-year and two-year AS in the carriers of the -2578A/A genotype was significantly higher than in the carriers of the -2578C/C genotype (p = 0.015 and p = 0.042 respectively). The identified influence of the polymorphic variants rs2010963 and rs699947 on the survival of NSCLC patients during the first three years after the established diagnosis shows a need to use knowledge about the genetic characteristics of a tumor during therapy.

немелкоклеточный рак легкогообщая выживаемостьскорректированная выживаемостьгенетический полиморфизмфактор роста эндотелия сосудовангиогенезnon-small cell lung canceroverall survivaladjusted survivalgenetic polymorphismvascular endothelial growth factorangiogenesisReferencesGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / H. Sung [et al.] // CA Cancer J. Clin. – 2021. – Vol. 71, N 3. – P. 209–249. https://doi.org/10.3322/caac.21660Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021, vol. 71, no. 3, pp. 209–249. https://doi.org/10.3322/caac.21660Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries / C. Allemani [et al.] // Lancet. – 2018. – Vol. 391, N 10125. – P. 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Nikšić M., Bonaventure A., Valkov M., Johnson C. J., Estève J., Ogunbiyi O. J., Azevedo e Silva G., Chen W. Q., Eser S., Engholm G., Stiller C. A., Monnereau A., Woods R. R., Visser O., Lim G. H., Aitken J., Weir H. K., Coleman M. P.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, vol. 391, no. 1025, pp. 1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3Folkman, J. Angiogenesis: an organizing principle for drug discovery? / J. Folkman // Nature Reviews Drug Discovery. – 2007. – Vol. 6. – P. 273–286. https://doi.org/10.1038/nrd2115Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature Reviews Drug Discovery, 2007, vol. 6, pp. 273–286. https://doi.org/10.1038/nrd2115Carmeliet, P. Molecular mechanisms and clinical applications of angiogenesis / Р. Carmeliet, R. K. Jain // Nature. – 2011. – Vol. 473. – P. 298–307. https://doi.org/10.1038/nature10144Carmeliet P., Jain R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, vol. 473, pp. 298–307. https://doi.org/10.1038/nature10144VEGF receptor signalling – in control of vascular function / A. K. Olsson [et al.] // Nat. Rev. Mol. Cell. Biol. – 2006. – Vol. 7. – P. 359–371. https://doi.org/10.1038/nrm1911Olsson A. K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nature Reviews Molecular Cell Biology, 2006, vol. 7, pp. 359–371. https://doi.org/10.1038/nrm1911Mathew, C. C. The isolation of high molecular weight eucaryotic DNA / C. C. Mathew // Methods in Molecular Biology: Nucleic Acids / ed. J. M. N. J. Walker. – Clifton, 1984. – Vol. 2, N 4. – P. 31–34. https://doi.org/10.1385/0-89603-064-4:31Mathew C. C. The isolation of high molecular weight eucaryotic DNA. Walker J. M. N. J., ed. Methods in Molecular Biology: Nucleic Acids. Clifton, 1984, vol. 2, pp. 31–34. https://doi.org/10.1385/0-89603-064-4:31Clinical and morphological characteristics of NSCLC and VEGF gene polymorphism / M. N. Shapetska [et al.] // Int. J. Adv. Res. – 2016. – Vol. 4. – P. 1802–1813. https://doi.org/10.21474/ijar01/1657Shapetska M. N., Shchayuk A. N., Mikhalenko E. P., Chebotareva N. V., Pisarchik S. N., Krupnova E. V. Clinical and morphological characteristics of NSCLC and VEGF gene polymorphism. International Journal of Advanced Research, 2016, vol. 4, pp. 1802–1813. https://doi.org/10.21474/ijar01/1657Association of vascular endothelial growth factor – a gene polymorphisms and haplotypes with breast cancer metastases / U. Langsenlehner [et al.] // Acta Oncol. – 2015. – Vol. 54, N 3. – P. 368–376. https://doi.org/10.3109/0284186x.2014.948056Langsenlehner U., Hofmann G., Renner W., Gerger A., Krenn-Pilko S., Thurner E.M., Krippl P., Langsenlehner T. Association of vascular endothelial growth factor – A gene polymorphisms and haplotypes with breast cancer metastases. Acta Oncology, 2015, vol. 54, no. 3, pp. 368–376. https://doi.org/10.3109/0284186x.2014.948056VEGF gene polymorphisms and susceptibility to rheumatoid arthritis / S. W. Han [et al.] // Rheumatology. – 2004. – Vol. 43, N 9. – P. 1173–1177. https://doi.org/10.1093/rheumatology/keh281Han S. W., Kim G. W., Seo J. S., Kim S. J., Sa K. H., Park J. Y., Lee J., Kim S. Y., Goronzy J. J., Weyand C. M., Kang Y. M. VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology (Oxford), 2004, vol. 43, no. 9, pp. 1173–1177. https://doi.org/10.1093/rheumatology/keh281Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection / M. Shahbazi [et al.] // J. Am. Soc. Nephrol. – 2002. – Vol. 13, N 1. – P. 260–264. https://doi.org/10.1681/asn.v131260Shahbazi M., Fryer A. A., Pravica V., Brogan I. J., Ramsay H. M., Hutchinson I. V., Harden P. N. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. Journal of the American Society of Nephrology, 2002, vol. 13, no. 1, pp. 260–264. https://doi.org/10.1681/asn.v131260A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels / W. Renner [et al.] // J. Vasc. Res. – 2000. – Vol. 37, N 6. – P. 443–448. https://doi.org/10.1159/000054076Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. Journal of Vascular Research, 2000, vol. 37, no. 6, pp. 443–448. https://doi.org/10.1159/000054076Functional interaction between p/CAF and human papillomavirus E2 protein / D. Lee [et al.] // J. Biol. Chem. – 2002. – Vol. 277, N 8. – P. 6483–6489. https://doi.org/10.1074/jbc.m105085200Lee D., Hwang S. G., Kim J., Choe J. Functional interaction between p/CAF and human papillomavirus E2 protein. Journal of Biological Chemistry, 2002, vol. 277, no. 8, pp. 6483–6489. https://doi.org/10.1074/jbc.m105085200Маркеры ангиогенеза при опухолевом росте / Н. А. Нефедова [и др.] // Архив патологии. – 2016. – Т. 78, № 2. – С. 55–62. https://doi.org/10.17116/patol201678255-62Nefedova N. A., Kharlova O. A., Danilova N. V., Malkov P. G., Gaifullin N. M. Markers of angiogenesis in tumor growth. Arkhiv Patologii, 2016, vol. 78, no. 2, pp. 55–62 (in Russian). https://doi.org/10.17116/patol201678255-62Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review / M. Tyczyńska [et al.] // J. Gastrointest Cancer. – 2021. – Vol. 52. – P. 476–488. https://doi.org/10.1007/s12029-021-00629-7Tyczyńska M., Kędzierawski P., Karakuła K., Januszewski J., Kozak K., Sitarz M., Forma A. Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review. Journal of Gastrointestinal Cancer, 2021, vol. 52, pp. 476–488. https://doi.org/10.1007/s12029-021-00629-7Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 / C. J. Allegra [et al.] // J. Clin. Oncol. – 2011. – Vol. 29, N 1. – P. 11–16. https://doi.org/10.1200/jco.2010.30.0855Allegra C. J., Yothers G., O’Connell M. J., Sharif S., Petrelli N. J., Colangelo L. H., Atkins J. N., Seay T. E., Fehrenbacher L., Goldberg R. M., O’Reilly S., Chu L., Azar C. A., Lopa S., Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. Journal of Clinical Oncology, 2011, vol. 29, no. 1, pp. 11–16. https://doi.org/10.1200/jco.2010.30.0855Bergers, G. Modes of resistance to anti-angiogenic therapy / G. Bergers, D. Hanahan // Nat. Rev. Cancer. – 2008. – Vol. 8. – P. 592–603. https://doi.org/10.1038/nrc2442Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 2008, vol. 8, pp. 592–603. https://doi.org/10.1038/nrc2442

The authors declare that there are no conflicts of interest present.